Understand what drives value in today’s medtech M&A market, from multiples and EBITDA to buyer strategy and deal timing.
The buyers who will set valuations are already asking AI-specific questions during initial conversations.
The lasting impression from AAOS 2026 is that the orthopedic industry is not waiting for the future.
Join us Wednesday May 13, 2026 at 12PM ET as MedWorld Advisors explores the value impacts of AI in MedTech in 2026 for MedTech companies at all stages of growth – from start-up to scale-up including operational excellence through M&A Exit.
Manufacturing-related AI can contribute to value because it improves performance in ways buyers can underwrite.
C-suites are being forced to include tariff dynamics into their short-term and long-term strategies.
Combining human expertise with AI creates safer, faster, and more innovative medtech solutions.
For the industry’s CDMOs, the future winners will not be defined by capacity or cost alone, but by their ability to co-engineer procedures.
In the first edition of 2026 of Today’s Medical Developments Magazine, MedWorld Advisors discusses how mergers and acquisitions will continue to play a strong role in shaping the next generation of MedTech industry innovation.
Medtech executives or board members with an eye toward a future liquidity event should start building intrinsic value in their respective organizations now.